|Bid||2.65 x 1000|
|Ask||3.75 x 900|
|Day's Range||2.60 - 2.92|
|52 Week Range||0.80 - 2.93|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2018 - May 11, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.56|
In June 2018, ContraFect Corp. (CFRX) had multiple presentations at the American Society for Microbiology (ASM) Microbe 2018 on the company’s lead drug candidate CF-301 and the Gram-negative lysin discovery program. This study was undertaken as part of ContraFect’s Gram-negative lysin discovery program. Gram-negative (GN) bacteria are responsible for a number of different bacterial infections and the emergence of antibiotic resistant strains is leading to a potential public health crisis.
ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Cara Cassino, M.D., the Company's Executive Vice President of Research and Development and Chief Medical Officer, will participate in an analyst-led fireside chat at the JMP Securities Life Sciences Conference on Thursday, June 21, 2018 at 1:30 PM ET in New York, NY. The chat will feature a one-on-one conversation followed by an interactive question and answer session. ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings.
88 Presentations by Coalition Members During the Annual Meeting WASHINGTON , June 6, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that 13 of its member companies will present ...
Glancy Prongay & Murray LLP continues its investigation on behalf of ContraFect Corporation investors concerning the Company and its directors’ and officers’ possible violations of state laws.
YONKERS, N.Y., May 30, 2018-- ContraFect Corporation, a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant ...
The catheter was removed as part of the patient’s care and segmented into different treatment groups: CF-301, daptomycin, or CF-301 + daptomycin with each compound used at concentrations of 1 μg/mL (a clinically relevant dose), 10 μg/mL, or 100 μg/mL. This study involved the use of an aortic valve infective endocarditis (IE) model in rabbits using methicillin-resistant Staphylococcus aureus (MRSA) strain MW2.
On a per-share basis, the Yonkers, New York-based company said it had a loss of 26 cents. Losses, adjusted for non-recurring costs, were 9 cents per share. The results matched Wall Street expectations. ...
YONKERS, N.Y., May 10, 2018-- ContraFect Corporation, a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant ...
71 Abstracts to be Presented by Coalition Members During the Annual Meeting WASHINGTON , April 20, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that thirteen of its member ...
Scientists in New York have found that a protein called lysin extracted from bacteriophage could lead to life-saving medicine to combat antibiotic-resistant infections. The drugs have reached the first human trials, after decades of research. Roselle Chen reports.
|Initiated||Chardan Capital: to Buy||6/15/2018|
|Initiated||William Blair: to Outperform||9/28/2016|
|Initiated||PiperJaffray: to Overweight||7/28/2016|
|Downgrade||Maxim Group: to||7/22/2016|
|Downgrade||Roth Capital: to Neutral||5/10/2016|
|Initiated||Roth Capital: to Buy||10/6/2014|
Full Time Employees: 23
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.